Avandia, Actos To Accelerate Market Growth With Rezulin's Withdrawal
Executive Summary
The removal of Warner-Lambert's Rezulin will boost sales of the two newer antidiabetic "glitazones," SmithKline Beecham/Bristol-Myers Squibb's Avandia and Lilly/Takeda's Actos.
You may also be interested in...
Liver Toxicity Guidance Urges Sponsors To Include Risky Patients In Trials
FDA's recent draft guidance on drug-induced liver injury recommends drug developers enroll patients with preexisting liver disease in at least Phase III clinical trials, especially if the drug might eventually be used in such patients.
Liver Toxicity Guidance Urges Sponsors To Include Risky Patients In Trials
FDA's recent draft guidance on drug-induced liver injury recommends drug developers enroll patients with preexisting liver disease in at least Phase III clinical trials, especially if the drug might eventually be used in such patients.
FDA Is Waiting On Internal Analysis Of Avandia Cardiovascular Safety Signal
FDA is not taking immediate regulatory action on an observed cardiovascular signal for GlaxoSmithKline's Avandia, as the agency feels the current labeling is sufficient until its own analysis of emerging safety data for the type 2 diabetes therapy is completed